Literature DB >> 20558385

Stem cell model of spinal muscular atrophy.

Allison D Ebert1, Clive N Svendsen.   

Abstract

Human embryonic stem cells provide a useful source of material for studying basic human development and various disease states. However, ethical issues concerning their procurement limit their acceptance and possible clinical applicability. Recent advances in stem cell technology have provided an alternative source of pluripotent stem cells that does not require the use of an embryo. This review addresses the generation of induced pluripotent stem cells from skin fibroblasts taken from various patient populations, with a specific focus on the pediatric disorder spinal muscular atrophy. These patient-derived cells may help researchers devise more appropriate therapies through a greater understanding of the molecular mechanisms that underlie neuron dysfunction and death in a variety of diseases. Furthermore, they provide an ideal platform for small-molecule screening and subsequent drug development.

Entities:  

Mesh:

Year:  2010        PMID: 20558385      PMCID: PMC3140872          DOI: 10.1001/archneurol.2010.89

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  32 in total

1.  SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens.

Authors:  C F Rochette; N Gilbert; L R Simard
Journal:  Hum Genet       Date:  2001-03       Impact factor: 4.132

2.  Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos.

Authors:  B Schrank; R Götz; J M Gunnersen; J M Ure; K V Toyka; A G Smith; M Sendtner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

3.  The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy.

Authors:  U R Monani; M Sendtner; D D Coovert; D W Parsons; C Andreassi; T T Le; S Jablonka; B Schrank; W Rossoll; W Rossol; T W Prior; G E Morris; A H Burghes
Journal:  Hum Mol Genet       Date:  2000-02-12       Impact factor: 6.150

4.  The survival motor neuron protein in spinal muscular atrophy.

Authors:  D D Coovert; T T Le; P E McAndrew; J Strasswimmer; T O Crawford; J R Mendell; S E Coulson; E J Androphy; T W Prior; A H Burghes
Journal:  Hum Mol Genet       Date:  1997-08       Impact factor: 6.150

5.  The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis.

Authors:  U Fischer; Q Liu; G Dreyfuss
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

6.  The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins.

Authors:  Q Liu; U Fischer; F Wang; G Dreyfuss
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

7.  Correlation between severity and SMN protein level in spinal muscular atrophy.

Authors:  S Lefebvre; P Burlet; Q Liu; S Bertrandy; O Clermont; A Munnich; G Dreyfuss; J Melki
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

8.  Valproic acid increases SMN levels in spinal muscular atrophy patient cells.

Authors:  Charlotte J Sumner; Thanh N Huynh; Jennifer A Markowitz; J Stephen Perhac; Brenna Hill; Daniel D Coovert; Kristie Schussler; Xiaocun Chen; Jill Jarecki; Arthur H M Burghes; J Paul Taylor; Kenneth H Fischbeck
Journal:  Ann Neurol       Date:  2003-11       Impact factor: 10.422

9.  Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy.

Authors:  L Brichta; Y Hofmann; E Hahnen; F A Siebzehnrubl; H Raschke; I Blumcke; I Y Eyupoglu; B Wirth
Journal:  Hum Mol Genet       Date:  2003-07-29       Impact factor: 6.150

10.  Identification and characterization of a spinal muscular atrophy-determining gene.

Authors:  S Lefebvre; L Bürglen; S Reboullet; O Clermont; P Burlet; L Viollet; B Benichou; C Cruaud; P Millasseau; M Zeviani
Journal:  Cell       Date:  1995-01-13       Impact factor: 41.582

View more
  10 in total

Review 1.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

Review 2.  Cellular therapy and induced neuronal replacement for Huntington's disease.

Authors:  Abdellatif Benraiss; Steven A Goldman
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 3.  Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience.

Authors:  Jerome Mertens; Maria C Marchetto; Cedric Bardy; Fred H Gage
Journal:  Nat Rev Neurosci       Date:  2016-05-19       Impact factor: 34.870

4.  Evaluation of cholesterol reduction activity of methyl-β-cyclodextrin using differentiated human neurons and astrocytes.

Authors:  Manju Swaroop; Natasha Thorne; Mahendra S Rao; Christopher P Austin; John C McKew; Wei Zheng
Journal:  J Biomol Screen       Date:  2012-08-24

Review 5.  Modeling neurological disorders by human induced pluripotent stem cells.

Authors:  Tanut Kunkanjanawan; Parinya Noisa; Rangsun Parnpai
Journal:  J Biomed Biotechnol       Date:  2011-11-24

6.  SMA Human iPSC-Derived Motor Neurons Show Perturbed Differentiation and Reduced miR-335-5p Expression.

Authors:  Michela Murdocca; Silvia Anna Ciafrè; Paola Spitalieri; Rosa Valentina Talarico; Massimo Sanchez; Giuseppe Novelli; Federica Sangiuolo
Journal:  Int J Mol Sci       Date:  2016-07-30       Impact factor: 5.923

Review 7.  miRNA in spinal muscular atrophy pathogenesis and therapy.

Authors:  Francesca Magri; Fiammetta Vanoli; Stefania Corti
Journal:  J Cell Mol Med       Date:  2017-11-21       Impact factor: 5.310

8.  Prenatal transplantation of human amniotic fluid stem cell could improve clinical outcome of type III spinal muscular atrophy in mice.

Authors:  Steven W Shaw; Shao-Yu Peng; Ching-Chung Liang; Tzu-Yi Lin; Po-Jen Cheng; T'sang-T'ang Hsieh; Hao-Yu Chuang; Paolo De Coppi; Anna L David
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

9.  Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiation.

Authors:  Suzy Varderidou-Minasian; Bert M Verheijen; Oliver Harschnitz; Sandra Kling; Henk Karst; W Ludo van der Pol; R Jeroen Pasterkamp; Maarten Altelaar
Journal:  ACS Omega       Date:  2021-12-15

10.  Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Have Reduced Expression of Proteins Important in Neuronal Development.

Authors:  Heidi R Fuller; Berhan Mandefro; Sally L Shirran; Andrew R Gross; Anjoscha S Kaus; Catherine H Botting; Glenn E Morris; Dhruv Sareen
Journal:  Front Cell Neurosci       Date:  2016-01-11       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.